论文部分内容阅读
目的对子宫内膜异位症患者术后应用孕三烯酮与米非司酮治疗,比较其临床疗效。方法选取子宫内膜异位症患者63例,根据治疗方法不同将其分为孕三烯酮组、米非司酮和对照组各21例。对照组单纯行腹腔镜保守手术治疗,孕三烯酮组在行保守手术后应用孕三烯酮治疗,米非司酮组在行保守手术后应用米非司酮治疗。对3组患者治疗后临床疗效、不良反应发生情况及生存质量评分进行比较。结果在治疗总有效率方面,孕三烯酮组为95.24%,米非司酮组为90.48%,对照组为66.67%,两组差异有统计学意义(P<0.05),但孕三烯酮组与米非司酮组比较差异无统计学意义(P>0.05);在复发率方面,孕三烯酮组为4.26%、米非司酮组为9.52%,两组均明显低于对照组(P<0.05),但孕三烯酮组与米非司酮组比较差异无统计学意义(P>0.05);在药物不良反应方面,米非司酮组明显低于与孕三烯酮组(19.05%vs.42.86%P<0.05)。在生存质量评分方面,孕三烯酮组与米非司酮组治疗后生存质量均较治疗前明显改善,与对照组比较均具有统计学意义(P<0.05)。结论对子宫内膜异位症患者术后应用孕三烯酮与米非司酮治疗的临床疗效显著,术后复发率较低,且能够明显改善患者生存质量,其中米非司酮药物不良反应更轻,值得临床推广应用。
Objective To evaluate the clinical efficacy of gestrinone and mifepristone in patients with endometriosis after operation. Methods 63 cases of endometriosis were selected, according to the different treatment methods were divided into gestrinone group, mifepristone and control group of 21 cases. The control group was treated with laparoscopic conservative surgery only. The gestoderpene group was treated with gestrinone after conservative surgery. The mifepristone group was treated with mifepristone after conservative surgery. Three groups of patients after treatment, clinical efficacy, adverse reactions and quality of life scores were compared. Results The total effective rate of treatment was 95.24% for gestrinone group, 90.48% for mifepristone group and 66.67% for control group, with significant difference between the two groups (P <0.05) There was no significant difference between the group and the mifepristone group (P> 0.05). The relapse rate was 4.26% in the gestrinone group and 9.52% in the mifepristone group, which were significantly lower than those in the control group (P <0.05), but there was no significant difference between the gestrinone group and the mifepristone group (P> 0.05). In adverse drug reactions, the mifepristone group was significantly lower than that of the gestrinone group (19.05% vs.42.86% P <0.05). In terms of quality of life score, the quality of life of gestrinone group and mifepristone group were significantly improved after treatment compared with that of the control group (all P <0.05). Conclusion The clinical efficacy of gestrinone and mifepristone in patients with endometriosis after operation is significant, the recurrence rate is low, and can significantly improve the quality of life of patients, including adverse effects of mifepristone Lighter, it is worth clinical application.